Embera NeuroTherapeutics, Inc., a Sudbury, MA, and Shreveport, LA-based clinical-stage pharmaceutical company, raised $2m in Series A-2 financing.
Backers included existing investors, angel groups, private individuals and HRA Pharma, based in Paris. HRA’s Chief Executive Officer, Erin Gainer, Ph.D., will serve as a non-voting observer to Embera’s Board of Directors.
Led by Bob Linke, Chief Executive Officer, Embera is a specialty biopharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions. It is developing a novel drug combination (EMB-001) targeting specific brain functions related to stress response that drive craving and relapse associated with these disorders.
The company intends to use the funds to complete a Phase 1, combined single and multiple rising dose clinical trial evaluating the safety and pharmacokinetics of EMB-001 in volunteers who smoke cigarettes but are otherwise healthy.